Andreas von Deimling, M.D.
Chairman Department of Neuropathology, University Heidelberg
And Head CCU Neuropathology, German Cancer Center
Positions and Employment
01/88 – 07/90
Department Neuropathology, University Hospital Zurich, Switzerland
08/90 – 07/92
Molecular Neuro-Oncology, Department of Neurosurgery and Molecular Neuro-Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, USA
08/92 – 04/94
Resident at the Department for Neuropathology, Bonn
09/95 – 08/98
Consultant at the Department for Neuropathology, Bonn
09/98 – 12/06
Director of the Department of Neuropathology, Charité, Berlin
01/07 – present
Director of the Department of Neuropathology, Heidelberg
01/07 – present
Director of CCU Neuropathology, DKFZ, Heidelberg
Honors
2009: Fellow of the European Academy of Cancer Sciences
2011: 7th A. Julio Martinez memorial lecture
2011: 3rd Abhijit Guha Oration Award (ISNO)
2012: Dorothy Russel Medal (BNS)
2016: Deutscher Krebspreis
2017: Fellow of the Leopoldina, the German National Academy of Sciences
2017: Fred W. Stewart Award
Research Field
Neuropathology of brain tumors with focus on molecular neuropathology
Achievements
1992: Description of allelic losses on 19q inoligodendroglial tumors
1993: Description of molecular subgroups in glioblastoma
1997: Description of molecular subgroups in oligoastrocytoma (either with oligodendroglioma or astrocytoma typical molecular alterations
2008: Detection of IDH1 mutations in diffuse glioma
2009: Development of IDH1-R132H mutation specific antibody H09
2011: Development of BRAF-V600E mutation specific antibody VE1
2013: Development of immunohistochemical detection of the NAB2-STAT6 fusion in hemangio pericytoma and SFT
2014-2015: Modification of the classification of diffuse glioma
current: Development of an CpG methylation based algorithm for the diagnosis of human brain tumors.
